NCT00738257View on ClinicalTrials.gov

A Prospective, Multicentre, Open-label Randomised Controlled Study to Investigate the Effectiveness of Pamidronate in the Prevention of Bone Loss in de Novo Renal Transplant Patients.

PHASE4CompletedINTERVENTIONAL
Enrollment

126

Participants

Timeline

Start Date

June 30, 2000

Primary Completion Date

December 31, 2004

Conditions
Bone Loss
Interventions
DRUG

Pamidronate

Trial Locations (1)

Unknown

Novartis Investigative Site, Frimley

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY

NCT00738257 - A Prospective, Multicentre, Open-label Randomised Controlled Study to Investigate the Effectiveness of Pamidronate in the Prevention of Bone Loss in de Novo Renal Transplant Patients. | Biotech Hunter | Biotech Hunter